Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
3.560
-0.040 (-1.11%)
Nov 1, 2024, 4:00 PM EDT - Market closed
Scinai Immunotherapeutics Employees
Scinai Immunotherapeutics had 31 employees as of December 31, 2023. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$9,161
Profits / Employee
-$119,484
Market Cap
2.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Venus Concept | 304 |
Molecular Templates | 62 |
iSpecimen | 53 |
Matinas BioPharma Holdings | 32 |
ReShape Lifesciences | 29 |
Sonnet BioTherapeutics Holdings | 12 |
Oragenics | 5 |
Tharimmune | 3 |
SCNI News
- 1 day ago - Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024 - PRNewsWire
- 6 weeks ago - Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies - PRNewsWire
- 7 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. - GlobeNewsWire
- 2 months ago - Scinai Regains Full Compliance with Nasdaq Listing Requirements - PRNewsWire
- 2 months ago - Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 - PRNewsWire
- 2 months ago - Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder - PRNewsWire
- 2 months ago - Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 - PRNewsWire